Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply
- PMID: 31067395
- DOI: 10.1056/NEJMc1902837
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply
Comment on
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019 May 9;380(19):1880-1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067393 No abstract available.
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019 May 9;380(19):1881. doi: 10.1056/NEJMc1902837. N Engl J Med. 2019. PMID: 31067394 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical